HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
-0.05%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$3.06B
AUM Growth
+$3.06B
(+19%)
Cap. Flow
+$516M
Cap. Flow
% of AUM
16.88%
Top 10 Holdings %
Top 10 Hldgs %
53.31%
Holding
44
New
8
Increased
13
Reduced
14
Closed
6
Top Buys
| 1 |
Merck
MRK
|
$181M |
| 2 |
Medtronic
MDT
|
$152M |
| 3 |
CELG
Celgene Corp
CELG
|
$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$122M |
| 5 |
Baxter International
BAX
|
$112M |
Top Sells
| 1 |
AET
Aetna Inc
AET
|
$180M |
| 2 |
Danaher
DHR
|
$105M |
| 3 |
Labcorp
LH
|
$75.3M |
| 4 |
Johnson & Johnson
JNJ
|
$68.2M |
| 5 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$66.1M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merck
MRK
$210B
| $219M | 7.14% | 3,900,000 +3,208,720 | +464% | +$181M |
|
|
BIVV
2
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $202M | 6.58% | 3,750,000 -400,000 | -10% | -$21.6M |
|
3
Zimmer Biomet
ZBH
$21B
| $184M | 5.99% | 1,525,000 -167,810 | -10% | -$20.2M |
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $180M | 5.86% | 1,725,000 +1,181,820 | +218% | +$123M |
|
|
5
Labcorp
LH
$23.1B
| $175M | 5.71% | 1,100,000 -472,290 | -30% | -$75.3M |
|
|
6
Medtronic
MDT
$119B
| $157M | 5.12% | 1,950,000 +1,883,900 | +2,850% | +$152M |
|
|
AGN
7
DELISTED
Allergan plc
AGN
| $135M | 4.39% | 825,000 +251,790 | +44% | +$41.2M |
|
8
Incyte
INCY
$16.5B
| $128M | 4.16% | 1,350,000 +751,450 | +126% | +$71.2M |
|
9
Pacira BioSciences
PCRX
$1.2B
| $128M | 4.16% | 2,800,000 +221,960 | +9% | +$10.1M |
|
|
10
Regeneron Pharmaceuticals
REGN
$61.5B
| $122M | 3.98% | +325,000 | New | +$122M |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $118M | 3.85% | 1,525,000 -562,110 | -27% | -$43.6M |
|
|
12
Baxter International
BAX
$12.7B
| $112M | 3.63% | +1,725,000 | New | +$112M |
|
13
Vertex Pharmaceuticals
VRTX
$100B
| $109M | 3.54% | 725,000 +690,050 | +1,974% | +$103M |
|
14
Haemonetics
HAE
$2.63B
| $84.2M | 2.74% | 1,450,000 -2,343 | -0.2% | -$136K |
|
15
CVS Health
CVS
$92.8B
| $81.6M | 2.65% | +1,125,000 | New | +$81.6M |
|
16
Intuitive Surgical
ISRG
$170B
| $80.8M | 2.63% | 221,470 +196,430 | +784% | +$71.7M |
|
17
IQVIA
IQV
$32.4B
| $76.7M | 2.5% | +783,380 | New | +$76.7M |
|
18
Sarepta Therapeutics
SRPT
$1.78B
| $72.9M | 2.37% | 1,309,960 +107,190 | +9% | +$5.96M |
|
19
AbbVie
ABBV
$372B
| $72.5M | 2.36% | 749,410 -236,910 | -24% | -$22.9M |
|
20
Elevance Health
ELV
$71.8B
| $71.1M | 2.32% | +316,180 | New | +$71.1M |
|
21
UnitedHealth
UNH
$281B
| $69.4M | 2.26% | 315,000 -67,990 | -18% | -$15M |
|
22
Pediatrix Medical
MD
$1.5B
| $67.4M | 2.19% | +1,261,620 | New | +$67.4M |
|
|
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
| $66.2M | 2.16% | 973,840 +326,420 | +50% | +$22.2M |
|
24
Humana
HUM
$36.5B
| $65.4M | 2.13% | 263,440 +2,570 | +1% | +$638K |
|
25
LivaNova
LIVN
$3.08B
| $49.8M | 1.62% | 622,997 -308,533 | -33% | -$24.7M |
|